## NME's APPROVED

**Infectious Diseases and Vaccines**
- **EU** Monovalent Ebola Vaccine
- **EU** Janssen COVID-19 Vaccine

**Neuroscience**
- **EU** SPRAVATO (esketamine)
- **US** PONVORY (ponesimod)

**Oncology**
- **EU** ERLEADA (apalutamide)
- **US** BALVERSA (erdafitinib)
- **US** RYBREVANT (amivantamab)

## NME's in REGISTRATION

**Infectious Diseases and Vaccines**
- Ebola virus Disease
- Janssen COVID-19 Vaccine

**Neuroscience**
- Treatment resistant depression
- Relapsing forms of multiple sclerosis

**Oncology**
- Non-metastatic prostate cancer
- Urothelial cancer
- Non Small Cell Lung Cancer

## NME PLANNED FILINGS 2021-2023

**Cardiovascular and Metabolism**
- **RPGR AAV Gene Therapy**
- aprocitentan
- **talcetamab (BCMA/CD3**

**Infectious Diseases and Vaccines**
- **RSV Sr. vaccine**

**Immunology**
- **nipocalimab**

**Neuroscience**
- **seltorexant**

## Selective Highlights as of July 21, 2021

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date listed to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.*

**BALVERSA** discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; **BCMA CAR-T** licensed from Imperial Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic; **EUMA** licensed from Bavarian Nordic A/S; **DUOBODY** platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab); Lentiviral licensed from Y harness Corporation; **Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3)** and **(X-Linked Retinitis Pigmentosa: AAV-RPGR)** licensed from MeiraGTx;